Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genitope has reported that it will suspend the development of MyVax personalized immunotherapy in previously untreated follicular B-cell non-Hodgkin's lymphoma patients.
Subscribe to our email newsletter
The decision is followed by the meeting with representatives of the FDA to discuss the previously announced failed results of company’s pivotal Phase III clinical trial of MyVax. The company is evaluating its alternatives with respect to the other aspects of its business, including development of its monoclonal antibody program.
Dan Denney, Jr., chairman and CEO of Genitope, said: “We greatly appreciate the support for MyVax that we have received from patients, clinicians, our employees and our stockholders. However, we recognize that the costs and time required for further clinical development of MyVax are prohibitive at this time, and we thus intend to focus our efforts on the development of our monoclonal antibody program.”